Curaleaf Files 6-K with Press Release on Feb 13

Ticker: CURLF · Form: 6-K · Filed: 2024-02-13T00:00:00.000Z

Sentiment: neutral

Topics: SEC Filing, Regulatory Disclosure, Corporate Update, Foreign Private Issuer

TL;DR

**Curaleaf filed a 6-K on Feb 13, including a press release, but the details aren't in this document.**

AI Summary

Curaleaf Holdings, Inc. filed a Form 6-K with the SEC on February 13, 2024, signed by Chief Legal Officer Peter Clateman. This regulatory filing, under Commission File Number 333-249081, indicates a material event and includes Exhibit 99.1, which is identified as a Press Release, though its specific content is not provided in this document.

Why It Matters

This 6-K filing signals that Curaleaf Holdings, Inc. is disclosing a material event or information to the public via a press release, which could impact investors, even though the specific details of that event are not included in this filing.

Risk Assessment

Risk Level: low — The filing itself is a routine regulatory disclosure, and without the content of the attached press release, no specific financial or operational risks are evident.

Key Numbers

Key Players & Entities

FAQ

What type of SEC filing is this document?

This document is a Form 6-K, a report of a foreign private issuer.

Who is the registrant for this filing?

The registrant is Curaleaf Holdings, Inc.

When was this report dated and filed?

The report is dated and was filed on February 13, 2024.

Who signed this report on behalf of Curaleaf Holdings, Inc.?

Peter Clateman, Chief Legal Officer, signed the report.

What exhibit is included with this 6-K filing?

Exhibit 99.1, described as a Press Release, is included with this filing.

From the Filing

0001756770-24-000007.txt : 20240213 0001756770-24-000007.hdr.sgml : 20240213 20240213135656 ACCESSION NUMBER: 0001756770-24-000007 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Curaleaf Holdings, Inc. CENTRAL INDEX KEY: 0001756770 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-249081 FILM NUMBER: 24624508 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 781-451-0117 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: LEAD VENTURES INC. DATE OF NAME CHANGE: 20181023 6-K 1 a6-kcover021324.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number: 333-249081 Curaleaf Holdings, Inc. (Name of Registrant) 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐    Form 40-F ☒ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CURALEAF HOLDINGS, INC. (Registrant) Date: February 13, 2024 By: /s/ Peter Clateman Name: Peter Clateman Title: Chief Legal Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated February 6, 2023 EX-99.1 2 pressrelease021324.htm EX-99.1 Document Curaleaf International Acquires Can4Med, Expanding Presence in Poland’s Growing Medical Cannabis Market London, February 6, 2024  – Curaleaf International (the "Company"), part of Curaleaf Holdings (TSX:CURA) and Europe's largest vertically integrated cannabis company, is pleased to announce its acquisition of Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland. This strategic move marks a significant milestone for both companies and underscores Curaleaf’s commitment to enhancing patient access to high-quality medical cannabis products across Europe. Poland boasts one of Europe’s largest patient populations seeking medical cannabis&#59; by joining forces with Can4Med, Curaleaf International gains a strong foothold in this dynamic market, allowing it to serve patients more effectively and expand its product offerings. “This acquisition represents a significant step forward for Curaleaf International. Poland’s medical cannabis market is expanding rapidly, and our partnership with Can4Med allows us to better serve patients while driving growth across Europe,” said Matt Darin, CEO of Curaleaf. "We are thrilled that Can4med, a pioneering force in Poland's cannabis market, has joined forces with Curaleaf, the global leader in cannabis. This acquisition marks a significant milestone in our journey, ensuring an unparalleled supply chain that positions us to meet and exceed the demands of the entire Polish market. Partnering with Curaleaf not only reinforces our commitment to quality and accessibility but also signifies a new era of growth and possibilities for both companies and our customers," said Maximilian Weinberg, founder of Can4med. As Poland positions itself at the forefront of the European cannabis market, its substantial population of 38 million is poised to catalyze sign

View on Read The Filing